Evidence map›Paper›PMID 39230499›Full record

ArticleAnnals of neurology2024

Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease.

Agustin Hidalgo-Gutierrez, Jonathan Shintaku, Javier Ramon, Eliana Barriocanal-Casado, Alba Pesini, Russell P Saneto, Gloria Garrabou, Jose Cesar Milisenda, Ana Matas-Garcia, Laura Gort and 18 more

Abstract readCase Reports
In one paragraph

Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Mitochondrial Transplantation as a Therapeutic Strategy for Inherited Mitochondrial Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Agustin Hidalgo-GutierrezDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-6414-6859
Jonathan ShintakuDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-2729-9009
Javier RamonBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-0673-9338
Eliana Barriocanal-CasadoDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-8828-1182
Alba PesiniDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-9695-7349
Russell P SanetoSeattle Children's Hospital, Seattle, WA.ORCID 0000-0002-7250-2347
Gloria GarrabouBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-8973-9933
Jose Cesar MilisendaBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-0151-7872
Ana Matas-GarciaBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Laura GortBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-4746-1034
Olatz UgarteburuBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-4214-3301
Yue GuDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
Lahari KogantiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
Tian WangDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.
Saba TadesseDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.
Megi MeneriDino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.ORCID 0000-0002-3429-1809
Monica SciaccoIRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Neuromuscular and Rare Disease Unit, Milan, Italy.ORCID 0000-0003-4593-4977
Shuang WangDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY.ORCID 0000-0002-1693-6888
Kurenai TanjiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-2230-2416
Marshall S HorwitzDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.ORCID 0000-0002-1683-1680
Michael O DorschnerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
Mahesh MansukhaniDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-2044-0751
Giacomo Pietro ComiDino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.ORCID 0000-0002-1383-5248
Dario RonchiDino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.ORCID 0000-0002-6093-9816
Ramon MartiBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-8273-9540
Antonia RibesBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-2249-246X
Frederic TortBiomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-2733-1603
Michio HiranoDepartment of Neurology, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0002-7070-7402

Funding

THERAPEUTIC APPROACHES IN MODELS OF MITOCHONDRIAL DIS.P01HD032062 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NAINI, ALI B. · 1995 to 2014
$24.4M
The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRANO, MICHIO · 2011 to 2023
$17.5M
Tech-CoreP01HD080642 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QUINZII, CATARINA M. · 2014 to 2018
$7.8M
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017:SGR 1428Agència de Gestió d'Ajuts Universitaris i de Recerca 2021:SGR 01423Common Fund 35GM139453Common Fund P01 HD32062Congressionally Directed Medical Research Programs W81XWH2010807Dino FerrariDipartimenti di EccellenzaEuropean Reference NetworkEuropean Regional Development FundFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SEQMD PNC-E3-2022-23683266Fundación Alfonso Martín EscuderoGeof BarkerHORIZON EUROPE 2021-2027 101065857Instituto de Salud Carlos III ER20P2AC737Instituto de Salud Carlos III PI19/01310Instituto de Salud Carlos III PI21/00554Instituto de Salud Carlos III PI22/00856JDM Fund for mitochondrial researchNICHD NIH HHS P01 HD032062NICHD NIH HHS P01 HD080642NINDS NIH HHS U54 NS078059Shuman Mitochondrial Disease FundationWellcome Trust 202020
6 · The paper itself

Abstract

objectiveMitochondrial DNA (mtDNA) depletion/deletions syndrome (MDDS) comprises a group of diseases caused by primary autosomal defects of mtDNA maintenance. Our objective was to study the etiology of MDDS in 4 patients who lack pathogenic variants in known genetic causes.

methodsWhole exome sequencing of the probands was performed to identify pathogenic variants. We validated the mitochondrial defect by analyzing mtDNA, mitochondrial dNTP pools, respiratory chain activities, and GUK1 activity. To confirm pathogenicity of GUK1 deficiency, we expressed 2 GUK1 isoforms in patient cells.

resultsWe identified biallelic GUK1 pathogenic variants in all 4 probands who presented with ptosis, ophthalmoparesis, and myopathic proximal limb weakness, as well as variable hepatopathy and altered T-lymphocyte profiles. Muscle biopsies from all probands showed mtDNA depletion, deletions, or both, as well as reduced activities of mitochondrial respiratory chain enzymes. GUK1 encodes guanylate kinase, originally identified as a cytosolic enzyme. Long and short isoforms of GUK1 exist. We observed that the long isoform is intramitochondrial and the short is cytosolic. In probands' fibroblasts, we noted decreased GUK1 activity causing unbalanced mitochondrial dNTP pools and mtDNA depletion in both replicating and quiescent fibroblasts indicating that GUK1 deficiency impairs de novo and salvage nucleotide pathways. Proband fibroblasts treated with deoxyguanosine and/or forodesine, a purine phosphatase inhibitor, ameliorated mtDNA depletion, indicating potential pharmacological therapies.

interpretationPrimary GUK1 deficiency is a new and potentially treatable cause of MDDS. The cytosolic isoform of GUK1 may contribute to the T-lymphocyte abnormality, which has not been observed in other MDDS disorders. ANN NEUROL 2024;96:1209-1224.

Indexed as

DNA, MitochondrialGuanylate KinasesMitochondrial DiseasesAdultChildExome SequencingFemaleFibroblastsHumansMaleDNA, MitochondrialGuanylate Kinases

Identifiers

PMID39230499
PMCPMC11563867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.